AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8823558 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 71
Study 1315661 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganciclovir
Number of subjects: 0
Study 1315661 — intervention group
Group type: EXPERIMENTAL
Intervention: Foscarnet
Number of subjects: 0
Study 1315661 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate treatment
Number of subjects: 0
Study 1315661 — intervention group
Group type: COMPARATOR
Intervention: Deferral of treatment
Number of subjects: 0
Study 6835563 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 35
Study 6835563 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 31607424 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopaminergic medication
Number of subjects: 0
Study 31607424 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study 31607424 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive impairment in PD patients
Number of subjects: 0
Study 29924010 — intervention group
Group type: EXPERIMENTAL
Intervention: LED therapy (n = 30)
Number of subjects: 60
Study 29924010 — intervention group
Group type: COMPARATOR
Intervention: Bath therapy (n = 30)
Number of subjects: 60
Study 27138968 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 30 mg twice daily
Number of subjects: 19
Study 27138968 — intervention group
Group type: COMPARATOR
Intervention: Microgynon 30® tablet (30 μg EE and 150 μg LN)
Number of subjects: 19
Study 24502751 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecological momentary assessment using the Daytime Insomnia Symptom Scale (DISS) administered 4 times daily for 7 days.
Number of subjects: 55
Study 19303591 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel verbs
Number of subjects: 0
Study 19303591 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel nouns
Number of subjects: 0
Study 19303591 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-course of mapping novel words
Number of subjects: 0
Study 15018324 — intervention group
Group type: EXPERIMENTAL
Intervention: Single intracisternal injection of recombinant tPA (400 microg/ml, 500 microg/ml, 700 microg/ml, 800 microg/ml in 20 ml distilled water at pH 7)
Number of subjects: 7
Study 15018324 — intervention group
Group type: EXPERIMENTAL
Intervention: Single intracisternal injection of recombinant tPA
Number of subjects: 7
Study 11136561 — intervention group
Group type: EXPERIMENTAL
Intervention: Class II radical hysterectomy
Number of subjects: 243
Study 11136561 — intervention group
Group type: COMPARATOR
Intervention: Class III radical hysterectomy
Number of subjects: 243
Study 10771973 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled dexamethasone
Number of subjects: 36
Study 10771973 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 7511229 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacing System Analyzer 1
Number of subjects: 99
Study 7511229 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacing System Analyzer 2
Number of subjects: 99
Study 7511229 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacing System Analyzer 3
Number of subjects: 99
Study 7511229 — intervention group
Group type: COMPARATOR
Intervention: Manual Measurement
Number of subjects: 99
Study 3044798 — intervention group
Group type: EXPERIMENTAL
Intervention: Six special blue fluorescent lamps with incubator sides draped with white cloth
Number of subjects: 101
Study 3044798 — intervention group
Group type: COMPARATOR
Intervention: Standard phototherapy units equipped with fluorescent lights
Number of subjects: 101
Study 3044798 — intervention group
Group type: COMPARATOR
Intervention: Halide lamp
Number of subjects: 101
Study 11980553 — intervention group
Group type: EXPERIMENTAL
Intervention: Published RCTs
Number of subjects: 447
Study 11980553 — intervention group
Group type: EXPERIMENTAL
Intervention: New therapy
Number of subjects: 447
Study 11980553 — intervention group
Group type: COMPARATOR
Intervention: Unpublished RCTs
Number of subjects: 447
Study 31048096 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouse-based contingent attention training (MCAT)
Number of subjects: 41
Study 31048096 — intervention group
Group type: COMPARATOR
Intervention: Control condition (free interpretation without feedback)
Number of subjects: 41
Study 30017261 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT)
Number of subjects: 91
Study 30017261 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 91
Study 30017261 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT) responders and remitters
Number of subjects: 91
Study 26931279 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide (TPTD) 20 μg/d (subcutaneous injection)
Number of subjects: 59
Study 26931279 — intervention group
Group type: COMPARATOR
Intervention: Zoledronic Acid (ZOL) 5 mg/yr (intravenous infusion)
Number of subjects: 59
Study 24852357 — intervention group
Group type: EXPERIMENTAL
Intervention: Previously received mental health treatment
Number of subjects: 266
Study 24852357 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 day depressive symptoms
Number of subjects: 266
Study 24852357 — intervention group
Group type: EXPERIMENTAL
Intervention: Private insurance
Number of subjects: 266
Study 24852357 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicaid
Number of subjects: 266
Study 24852357 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol abuse and prior mental health care
Number of subjects: 266
Study 23268574 — intervention group
Group type: EXPERIMENTAL
Intervention: Trap door (TD) technique
Number of subjects: 13
Study 23268574 — intervention group
Group type: COMPARATOR
Intervention: Triangular distal wedge (TW) procedure
Number of subjects: 13
Study 20391044 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyanocobalamin nasal spray for 8 weeks
Number of subjects: 36
Study 20391044 — intervention group
Group type: COMPARATOR
Intervention: None (Control group)
Number of subjects: 36
Study 18586810 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training and stretching
Number of subjects: 101
Study 18586810 — intervention group
Group type: COMPARATOR
Intervention: Stretching only
Number of subjects: 101
Study 15824145 — intervention group
Group type: EXPERIMENTAL
Intervention: RARbeta2 P2 promoter methylation in early stage breast cancers
Number of subjects: 38
Study 15824145 — intervention group
Group type: EXPERIMENTAL
Intervention: RARbeta2 P2 promoter methylation in RPFNA samples
Number of subjects: 38
Study 15824145 — intervention group
Group type: EXPERIMENTAL
Intervention: RARbeta2 P2 promoter methylation stratified by Masood cytology index
Number of subjects: 38
Study 12094192 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy with ST-segment resolution at 90 minutes
Number of subjects: 2352
Study 12094192 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy with ST-segment resolution at 180 minutes
Number of subjects: 2352
Study 12094192 — intervention group
Group type: EXPERIMENTAL
Intervention: ST-segment resolution at 90 minutes
Number of subjects: 2352
Study 12094192 — intervention group
Group type: EXPERIMENTAL
Intervention: ST-segment resolution at 180 minutes
Number of subjects: 2352
Study 12094192 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients aged >70 years, Killip class >1, and anterior infarctions
Number of subjects: 2352
Study 10340829 — intervention group
Group type: EXPERIMENTAL
Intervention: Monovalent antivenom (ammonium sulphate fractionation)
Number of subjects: 53
Study 10340829 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyvalent antivenom (caprylic acid fractionation)
Number of subjects: 53
Study 10340829 — intervention group
Group type: COMPARATOR
Intervention: Both antivenoms
Number of subjects: 53
Study 10340829 — intervention group
Group type: EXPERIMENTAL
Intervention: Monovalent antivenom
Number of subjects: 53
Study 8948272 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 10 mg/day
Number of subjects: 478
Study 8948272 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 20/5 mg
Number of subjects: 478
Study 8948272 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 5 mg
Number of subjects: 478
Study 8948272 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate treatment
Number of subjects: 478
Study 8948272 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 478
Study 8948272 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 478
Study 1682685 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin (NANC stimulant)
Number of subjects: 24
Study 6751268 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical surgery only (Wertheim‐Meigs)
Number of subjects: 60
Study 6751268 — intervention group
Group type: COMPARATOR
Intervention: Radical surgery followed by postoperative external radiotherapy
Number of subjects: 60
Study 31335587 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin users
Number of subjects: 303
Study 31335587 — intervention group
Group type: COMPARATOR
Intervention: Non-users
Number of subjects: 303
Study 29921404 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of contraceptive pill + local treatment + pulsed‐vacuum light (Group I)
Number of subjects: 116
Study 29921404 — intervention group
Group type: EXPERIMENTAL
Intervention: Contraceptives + pulsed‐vacuum light (Group II)
Number of subjects: 116
Study 29921404 — intervention group
Group type: COMPARATOR
Intervention: Local treatment only (Group III)
Number of subjects: 116
Study 29921404 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of contraceptives + pulsed‐vacuum light (Group II)
Number of subjects: 116
Study 27208343 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.2 mg
Number of subjects: 72
Study 27208343 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg
Number of subjects: 72
Study 27208343 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 0.6 mg
Number of subjects: 72
Study 27208343 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 25057173 — intervention group
Group type: EXPERIMENTAL
Intervention: Vandetanib (100 mg/day) plus docetaxel (75 mg/m(2) every 21 days)
Number of subjects: 1391
Study 25057173 — intervention group
Group type: EXPERIMENTAL
Intervention: Vandetanib plus docetaxel
Number of subjects: 1391
Study 25057173 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus docetaxel
Number of subjects: 1391
Study 22173910 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavanol-rich chocolate (FRC)
Number of subjects: 20
Study 22173910 — intervention group
Group type: COMPARATOR
Intervention: Cocoa-liquor-free control chocolate (CC)
Number of subjects: 20
Study 19171948 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep group (practiced in the evening, retention testing the following morning)
Number of subjects: 0
Study 19171948 — intervention group
Group type: COMPARATOR
Intervention: No-sleep group (practiced in the morning, retention testing in the evening)
Number of subjects: 0
Study 19171948 — intervention group
Group type: COMPARATOR
Intervention: Control participants (not specified if they practiced in the evening or morning)
Number of subjects: 0
Study 17205032 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin 200 mg intravenously twice a day
Number of subjects: 90
Study 17205032 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide 10 mg intravenously four times daily
Number of subjects: 90
Study 17205032 — intervention group
Group type: EXPERIMENTAL
Intervention: Rescue combination therapy (open-label)
Number of subjects: 90
Study 15867118 — intervention group
Group type: EXPERIMENTAL
Intervention: Skill-based HIV/STD intervention
Number of subjects: 682
Study 15867118 — intervention group
Group type: COMPARATOR
Intervention: Information-based HIV/STD intervention
Number of subjects: 682
Study 15867118 — intervention group
Group type: COMPARATOR
Intervention: Health promotion control intervention
Number of subjects: 682
Study 12509907 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinnitus retraining therapy (TRT) with drugs
Number of subjects: 225
Study 12509907 — intervention group
Group type: COMPARATOR
Intervention: Control group with tinnitus masking and drugs
Number of subjects: 225
Study 9801090 — intervention group
Group type: EXPERIMENTAL
Intervention: External beam radiation for prostate cancer (PFH group)
Number of subjects: 920
Study 9801090 — intervention group
Group type: COMPARATOR
Intervention: External beam radiation for prostate cancer (Sporadic group)
Number of subjects: 920
Study 7644082 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sumatriptan 25 mg, 50 mg, or 100 mg
Number of subjects: 259
Study 7644082 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 259
Study 2503080 — intervention group
Group type: EXPERIMENTAL
Intervention: Support with human chorionic gonadotrophin (2500 IU) given three and six days after ovulation induction with 10,000 IU human chorionic gonadotrophin.
Number of subjects: 115
Study 2503080 — intervention group
Group type: COMPARATOR
Intervention: No hormonal support (control group).
Number of subjects: 115
Study 2503080 — intervention group
Group type: EXPERIMENTAL
Intervention: Support with human chorionic gonadotrophin (2500 IU).
Number of subjects: 115
Study 952109 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined polychemotherapy with high doses of cytostatics applied intermittently after radical surgery.
Number of subjects: 220
Study 952109 — intervention group
Group type: COMPARATOR
Intervention: Radical surgical operation without aftertreatment.
Number of subjects: 220
Study 31271312 — intervention group
Group type: EXPERIMENTAL
Intervention: self‐monitoring of blood glucose and four sensor wears (group C)
Number of subjects: 148
Study 31271312 — intervention group
Group type: COMPARATOR
Intervention: self‐monitoring of blood glucose (group A)
Number of subjects: 148
Study 28866675 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg or Bevacizumab 1.25 mg (2 intravitreal loading doses at 4-week intervals)
Number of subjects: 50
Study 28866675 — intervention group
Group type: COMPARATOR
Intervention: Dry AMD (control group)
Number of subjects: 50
Study 25458726 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal corticosteroids (1052 of 2327 women, 45%)
Number of subjects: 47494
Study 25458726 — intervention group
Group type: COMPARATOR
Intervention: Standard care (215 of 2062 women, 10%)
Number of subjects: 47494
Study 25458726 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal corticosteroids (whole population)
Number of subjects: 47494
Study 25458726 — intervention group
Group type: COMPARATOR
Intervention: Standard care (whole population)
Number of subjects: 47494
Study 23744759 — intervention group
Group type: EXPERIMENTAL
Intervention: HPβCD-diclofenac (IV)
Number of subjects: 0
Study 23744759 — intervention group
Group type: EXPERIMENTAL
Intervention: HPβCD-diclofenac (IM)
Number of subjects: 0
Study 23744759 — intervention group
Group type: EXPERIMENTAL
Intervention: HPβCD-diclofenac (IV) 18.75 mg
Number of subjects: 0
Study 23744759 — intervention group
Group type: EXPERIMENTAL
Intervention: HPβCD-diclofenac (IV) 37.5 mg
Number of subjects: 0
Study 23744759 — intervention group
Group type: COMPARATOR
Intervention: Cataflam 50 mg (oral)
Number of subjects: 0
Study 21816980 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 814
Study 21816980 — intervention group
Group type: COMPARATOR
Intervention: Glipizide
Number of subjects: 814
Study 19736496 — intervention group
Group type: EXPERIMENTAL
Intervention: Management of HCV in hemodialysis patients at Prince Salman Center for kidney disease (PSCKD)
Number of subjects: 0
Study 19736496 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalence of HCV in hemodialysis patients in Saudi Arabia
Number of subjects: 0
Study 17147046 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium enoxaparin administered subcutaneously at a dose of 4,000 IU once a day for 10 days, combined with venovenous hemofiltration performed at the first and last day of the protocol
Number of subjects: 20
Study 17147046 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (cortisone, vasoactive agents, and vitamin complexes) administered in physiological solution intravenously twice daily for 10 days
Number of subjects: 20
Study 12626791 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct access (no routine follow-up but access to rapid review on request)
Number of subjects: 209
Study 12626791 — intervention group
Group type: COMPARATOR
Intervention: Routine review (control)
Number of subjects: 209
Study 10840422 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly BCG
Number of subjects: 236
Study 10840422 — intervention group
Group type: COMPARATOR
Intervention: Alternating monthly interferon-alpha and BCG
Number of subjects: 236
Study 9175061 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonographic guidance for catheter insertion (Group A)
Number of subjects: 0
Study 9175061 — intervention group
Group type: COMPARATOR
Intervention: Blind technique for catheter insertion (Group B)
Number of subjects: 0
Study 8269913 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 51
Study 8269913 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 51
Study 8269913 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin and Carbamazepine
Number of subjects: 51
Study 3107462 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin (800 mg)
Number of subjects: 168
Study 3107462 — intervention group
Group type: COMPARATOR
Intervention: Thiamphenicol (2.5 g)
Number of subjects: 168
Study 30730452 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing bedside report
Number of subjects: 0
Study 30730452 — intervention group
Group type: COMPARATOR
Intervention: Control group (not participating in nursing bedside report)
Number of subjects: 0
Study 28285862 — intervention group
Group type: EXPERIMENTAL
Intervention: Vapocoolant spray
Number of subjects: 40
Study 28285862 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA cream
Number of subjects: 40
Study 28285862 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified, but implied as the pain without intervention)
Number of subjects: 40
Study 27987591 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib plus pemetrexed
Number of subjects: 713
Study 27987591 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus pemetrexed
Number of subjects: 713
Study 24394586 — intervention group
Group type: EXPERIMENTAL
Intervention: Cantilevered fixed dental prostheses (CFDPs)
Number of subjects: 62
Study 24394586 — intervention group
Group type: COMPARATOR
Intervention: Natural second premolar (non-cantilever group)
Number of subjects: 62
Study 22879908 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 64
Study 22879908 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 20002719 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol 15 mg/kg/dose every 4 h
Number of subjects: 100
Study 20002719 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen 10 mg/kg/dose every 8 h
Number of subjects: 100
Study 20002719 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol and Ibuprofen (both groups)
Number of subjects: 100
Study 17362317 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin/cisplatin/paclitaxel (TAP)
Number of subjects: 134
Study 17362317 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin/cisplatin (AP)
Number of subjects: 134
Study 17362317 — intervention group
Group type: EXPERIMENTAL
Intervention: TAP
Number of subjects: 134
Study 12765607 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibodies against beta-amyloid (aggregated Abeta(42))
Number of subjects: 30
Study 12765607 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 10905644 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoldopam 0.1 microg/kg/min
Number of subjects: 107
Study 10905644 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoldopam 0.3 microg/kg/min
Number of subjects: 107
Study 10905644 — intervention group
Group type: COMPARATOR
Intervention: Fenoldopam 0.01 microg/kg/min
Number of subjects: 107
Study 10905644 — intervention group
Group type: COMPARATOR
Intervention: Fenoldopam 0.03 microg/kg/min
Number of subjects: 107
Study 9140791 — intervention group
Group type: EXPERIMENTAL
Intervention: Bunazosin
Number of subjects: 358
Study 9140791 — intervention group
Group type: COMPARATOR
Intervention: Nitrendipine
Number of subjects: 358
Study 1419452 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg
Number of subjects: 110
Study 1419452 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg
Number of subjects: 110
Study 1419452 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine 40 mg
Number of subjects: 110
Study 1419452 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 6145426 — intervention group
Group type: EXPERIMENTAL
Intervention: fluperlapine 5 mg
Number of subjects: 8
Study 6145426 — intervention group
Group type: EXPERIMENTAL
Intervention: fluperlapine 10 mg
Number of subjects: 8
Study 6145426 — intervention group
Group type: EXPERIMENTAL
Intervention: clozapine 5 mg
Number of subjects: 8
Study 6145426 — intervention group
Group type: EXPERIMENTAL
Intervention: clozapine 10 mg
Number of subjects: 8
Study 6145426 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 8
Study 3527402 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorambucil (CB) and Prednisone (P) for induction therapy
Number of subjects: 178
Study 3527402 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorambucil (CB) and Prednisone (P) for consolidation
Number of subjects: 178
Study 3527402 — intervention group
Group type: COMPARATOR
Intervention: Cytosine arabinoside and Cyclophosphamide for consolidation
Number of subjects: 178
Study 3527402 — intervention group
Group type: EXPERIMENTAL
Intervention: Responders (CR + PR)
Number of subjects: 178
Study 29895236 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression garment (18-21 mmHg) worn on one calf until follow-up
Number of subjects: 0
Study 29895236 — intervention group
Group type: COMPARATOR
Intervention: Control (non-compressed calf)
Number of subjects: 0
Study 29200573 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS)
Number of subjects: 1
Study 29200573 — intervention group
Group type: COMPARATOR
Intervention: Sham (Control)
Number of subjects: 1